Cerebroside sulfatase

Drug Profile

Cerebroside sulfatase

Alternative Names: Arylsulfatase A; HGT-1110; HGT-1111; Metazym; Recombinant human arylsulfatase A; Recombinant human cerebroside sulfatase; Recombinant human sulfatidate sulfatase; rhASA; SHP-611; Sulfatide sulfatase

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Zymenex A/S
  • Developer Assistance Publique Hopitaux de Paris; Shire; Zymenex A/S
  • Class Arylsulfatases; Recombinant proteins
  • Mechanism of Action Cerebroside sulfatase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Metachromatic leukodystrophy
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Metachromatic leukodystrophy

Most Recent Events

  • 01 Jan 2017 Shire completes a phase I/II trial in Metachromatic leukodystrophy (Intrathecal) in Australia, Denmark, Japan, France and Germany (NCT01510028)
  • 05 Aug 2016 Cerebroside sulfatase is still in phase I/II trials for Metachromatic leukodystrophy (In children) in Australia, Japan, Denmark, France and Germany (Shire Form 10-Q, August 2016)
  • 30 May 2014 Shire completes enrolment in a phase I/II trial in Metachromatic leukodystrophy (Intrathecal) in Australia, Denmark, France and Germany (NCT01510028)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top